Compare ARAY & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARAY | CCEL |
|---|---|---|
| Founded | 1990 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 30.9M |
| IPO Year | 2006 | 2022 |
| Metric | ARAY | CCEL |
|---|---|---|
| Price | $0.25 | $4.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 497.6K | 14.2K |
| Earning Date | 05-06-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 4.26% |
| EPS Growth | ★ 87.50 | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $25,384,279.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.58 | N/A |
| P/E Ratio | ★ N/A | $62.86 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $0.22 | $2.72 |
| 52 Week High | $2.10 | $5.01 |
| Indicator | ARAY | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 52.90 |
| Support Level | $0.23 | $3.04 |
| Resistance Level | $0.33 | $4.38 |
| Average True Range (ATR) | 0.02 | 0.25 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 12.33 | 25.00 |
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. The company has one operating segment which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.